Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach

References

• Allen, B. K., Mehta, S., Ember, S. W. J., Zhu, J.-Y., Schönbrunn, E., Ayad, N. G., & Schüre, S. C. (2017). Identification of a novel class of BRD4 inhibitors by computational screening and binding simulations. ACS Omega, 2, 4760–4771. https://doi.org/10.1021/acsomega.7b00553
   PubMed Web of Science ®Google Scholar
• Al-Sha’er, M. A., Al-Balas, Q. A., Hassan, M. A., Al Jabal, G. A., & Almaaytah, A. M. (2019). Combination of pharmacophore modeling and 3D-QSAR analysis of potential glyoxalase-I inhibitors as anticancer agents. Computational Biology and Chemistry, 80, 102–110. https://doi.org/10.1016/j.compbiolchem.2019.03.011
   PubMed Web of Science ®Google Scholar
• Ayad, N. G., & Schu, S. C. (2017). Identification of a novel class of BRD4 inhibitors by computational screening and binding simulations. ACS Omega, 2, 4760–4771. https://doi.org/10.1021/acsomega.7b00553
   PubMed Web of Science ®Google Scholar
• Bryce, K. A., Mehta, S., Ember, S. W. J., Zhu, J.-Y., Schönbrunn, E., Ayad, N. G., & Schürer, S. C. (2017). Identification of a novel class of BRD4 inhibitors by computationalscreening and binding simulations. ACS Omega, 2(8), 4760–4771. https://doi.org/10.1021/acsomega.7b00553
   PubMed Web of Science ®Google Scholar
• Charuvaka, M., Azhagiya Singam, E. R., Sundar Raman, S., & Subramanian, V. (2014). Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. Molecular BioSystems, 10(9), 2384–2397. https://doi.org/10.1039/c4mb00243a.
   PubMedGoogle Scholar
• Chen, L., Morrow, J. K., Tran, H. T., Phatak, S. S., Du-Cuny, L., & Zhang, S. (2012). From laptop to benchtop to bedside: structure-based drug design on protein targets. Current Drug Metabolism, 18(9), 1217–1239. https://doi.org/10.2174/138920012799362837
   Google Scholar
• Chung, C-w., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., & Magny, S. M. (2011). Discovery and characterization of small molecule inhibitors of the BET family bromodomains. Journal of Medical Chemistry, 54(11), 3827–3838. https://doi.org/10.1021/jm200108t
   PubMed Web of Science ®Google Scholar
• Dupper, N. J., Zhou, Y., Govin, J., & McKenna, C. E. (2019). Bromodomain inhibition and its application to human disease. Pharmacoepigenetics, 483–488. https://doi.org/10.1016/B978-0-12-813939-4.00011-5
   Google Scholar
• Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., … Bradner, J. E. (2010). Selective Inhibition of BET Bromodomains. Nature, 468(7327), 1067–1073. https://doi.org/10.1038/nature09504
   PubMed Web of Science ®Google Scholar
• Fujisawa, T., & Filippakopoulos, P. (2017). Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nature Reviews Molecular Cell Biology, 18(4), 246–262. https://doi.org/10.1038/nrm.2016.143
   PubMed Web of Science ®Google Scholar
• Garnier, J-m., Sharp, P. P., Burns, C. J., Garnier, J-m., Sharp, P. P., & Burns, C. J. (2014). Expert opinion on therapeutic patents BET bromodomain inhibitors : A patent review BET bromodomain inhibitors : A patent review. Expert Opinion on Therapeutic Patents 3776. https://doi.org/10.1517/13543776.2014.859244
   Web of Science ®Google Scholar
• Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Leblanc, Y., Côté, A., Nasveschuk, C. G., Taylor, A. M., Harmange, J.-C., Audia, J. E., Pardo, E., Joshi, S., Sandy, P., Mertz, J. A., Sims, R. J., Bergeron, L., Bryant, B. M., Bellon, S., Poy, F., Jayaram, H., … Albrecht, B. K. (2013). Discovery, design, and optimization of isoxazole azepine BET inhibitors. ACS Medicinal Chemistry Letters, 4(9), 835–840. https://doi.org/10.1021/ml4001485
   PubMed Web of Science ®Google Scholar
• Ghoshal, A., Yugandhar, D., & Srivastava, A. K. (2016). BET inhibitors in cancer therapeutics : A Patent review. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2016.1159299
   PubMed Web of Science ®Google Scholar
• Gil, J., Ramírez-Torres, A., & Encarnación-Guevara, S. (2017). Lysine acetylation and cancer: A proteomics perspective. Journal of Proteomics, 150, 297–309. https://doi.org/10.1016/j.jprot.2016.10.003
   PubMed Web of Science ®Google Scholar
• Hassanpour, S. H., & Dehghani, M. (2017). Review of cancer from perspective of molecular. Journal of Cancer Research and Practice, 4(4), 127–129. https://doi.org/10.1016/j.jcrpr.2017.07.001
   Google Scholar
• Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016). In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med., 8(3), 186–210. https://doi.org/10.1002/wsbm.1337
   Google Scholar
• Liang, D., Yu, Y., & Ma, Z. (2020). Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. European Journal of Medicinal Chemistry, 200, 112426. https://doi.org/10.1016/j.ejmech.2020.112426
   PubMed Web of Science ®Google Scholar
• Ligand, I., Tahir, A., Alharthy, R. D., Naseem, S., Mahmood, N., & Id, M. A. (2018). Investigations of structural requirements for BRD4 inhibitors through ligand- and structure -based 3D QSAR approaches. Molecules, 23, 1527. https://doi.org/10.3390/molecules23071527
   PubMed Web of Science ®Google Scholar
• Lu, T., Lu, W., & Luo, C. (2020). Ac Ce Pt Cr T. Expert opinion on therapeutic patents, 1. https://doi.org/10.1080/13543776.2020.1702645
   PubMedGoogle Scholar
• Mujtaba, S., Zeng, L., & Zhou, M. M. (2007). Structure and acetyl-lysine recognition of the bromodomain. Oncogene, 26(37), 5521–5527. https://doi.org/10.1038/sj.onc.1210618
   PubMed Web of Science ®Google Scholar
• Muvva, C., Azhagiya Singam, E. R., Sundar Raman, S., & Subramanian, V. (2014). Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. Molecular BioSystems, 10(9), 2384–2397. https://doi.org/10.1039/C4MB00243A
   PubMedGoogle Scholar
• Noguchi-Yachide, T. (2019). Regulators of histone acetylation : Bromodomain inhibitors. In Pharmacoepigenetics (pp. 463–472). Elsevier. https://doi.org/10.1016/B978-0-12-813939-4.00010-3
   Google Scholar
• Ocaña, A., Nieto-Jiménez, C., & Pandiella, A. (2017). BET Inhibitors as novel therapeutic agents in breast cancer. Oncotarget, 8(41), 71285–71291. https://doi.org/10.18632/oncotarget.19744
   PubMedGoogle Scholar
• Pattar, S. V., Adhoni, S. A., Kamanavalli, C. M., & Kumbar, S. S. (2020). In silico molecular docking studies and MM/GBSA analysis of coumarin- carbonodithioate hybrid derivatives divulge the anticancer potential against breast cancer. Beni-Suef University Journal of Basic and Applied Sciences, 9(36), 1–10. https://doi.org/10.1186/s43088-020-00059-7
   Google Scholar
• Raj, U., Kumar, H., & Varadwaj, P. K. (2016). Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors. Journal of Biomolecular Structure and Dynamics, 35(11), 2351–2362. https://doi.org/10.1080/07391102.2016.1217276
   PubMed Web of Science ®Google Scholar
• Ran, T., Zhang, Z., Liu, K., Lu, Y., Li, H., Xu, J., Xiong, X., Zhang, Y., Xu, A., Lu, S., Liu, H., Lu, T., & Chen, Y. (2015). Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation. Molecular BioSystems, 11(5), 1295–1304. https://doi.org/10.1039/C4MB00723A
   PubMedGoogle Scholar
• Saravanan, K. M., Zhang, H., Senthil, R., Kumar, K., Sounderrajan, V., & Wei, Y. (2020). Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds medicinal plant-derived antiviral compounds. Journal of Biomolecular Structure and Dynamics, 40(5), 1970–1978. https://doi.org/10.1080/07391102.2020.1834457
   PubMed Web of Science ®Google Scholar
• Shao, M., He, L., Zheng, L., Huang, L., Zhou, Y., Wang, T., Chen, Y., Shen, M., Wang, F., Yang, Z., & Chen, L. (2017). Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters, 27(17), 4051–4055. https://doi.org/10.1016/j.bmcl.2017.07.054
   PubMed Web of Science ®Google Scholar
• Stathis, A., & Bertoni, F. (2018). BET Proteins as targets for anticancer treatment. Cancer Discovery, 8(1), 24–36. https://doi.org/10.1158/2159-8290.CD-17-0605
   PubMed Web of Science ®Google Scholar
• Su, J., Liu, X., Zhang, S., Yan, F., & Zhang, Q. (2017). A computational insight into binding modes of containing protein 4 based on molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics. 1102, 1–13. https://doi.org/10.1080/07391102.2017.1317666
   Google Scholar
• Tumdam, R., Kumar, A., Subbarao, N., & Balaji, B. S. (2018). In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein : BRD4-BD1. SAR and QSAR in Environmental Research, 29(12), 975–996. https://doi.org/10.1080/1062936X.2018.1537301
   PubMed Web of Science ®Google Scholar
• Wakchaure, P., Velayutham, R., & Roy, K. K. (2019). Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4. Journal of Biomolecular Structure and Dynamics, 37(12), 3048–3057. https://doi.org/10.1080/07391102.2018.1507838
   PubMed Web of Science ®Google Scholar
• Wang, B., Koot, D., Kasonga, A., Stander, X. X., & Stander, A. (2016). In silico. https://doi.org/10.1111/ijlh.12426
   Google Scholar
• White, M. E., Fenger, J. M., & Carson, W. E. (2019). Emerging roles of and therapeutic strategies targeting BRD4 in cancer. Cellular Immunology, 337(February), 48–53. https://doi.org/10.1016/j.cellimm.2019.02.001
   PubMedGoogle Scholar
• Xu, Y., & Vakoc, C. R. (2017). Targeting cancer cells with BET bromodomain inhibitors. Cold Spring Harb Perspect Med, 7, 1–18. https://doi.org/10.1101/cshperspect.a026674
   Web of Science ®Google Scholar
• Yan, G., Hou, M., Luo, J., Pu, C., Hou, X., Lan, S., & Li, R. (2018). Pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation and biological evaluation for the discovery of novel BRD4 inhibitors. Chemical Biology & Drug Design, 91(2), 478–490. https://doi.org/10.1111/cbdd.13109
   Google Scholar
• Yousuf, Z., Iman, K., Iftikhar, N., & Mirza, M. U. (2017). Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer. Breast Cancer (Dove Medical Press), 9, 447–459. https://doi.org/10.2147/BCTT.S132074
   PubMed Web of Science ®Google Scholar
• Zhang, G., Plotnikov, A. N., Rusinova, E., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M., & Zhou, M-m (2013). Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. Journal of Medicinal Chemistry, 56(22), 9251–9264. https://doi.org/10.1021/jm401334s
   PubMed Web of Science ®Google Scholar